Daxor Pushes Next-Gen Blood Volume Tech at MedAxiom CV Transforum

  • Daxor showcasing its FDA-cleared BVA platform at MedAxiom CV Transforum Fall '26 in Denver, October 22–24, 2026.
  • Next-gen BVA operates 3x faster, requires 50% less sample volume, and delivers >95% measurement accuracy.
  • Company aims to reduce 30-day readmissions and optimize length of stay in cardiovascular care.
  • Daxor's commercial leadership hosting platform demonstrations for cardiovascular service line directors and CFOs.

Daxor's push at MedAxiom CV Transforum underscores the growing emphasis on precision diagnostics in cardiovascular care, where traditional methods often lead to suboptimal outcomes. The company's focus on value-based care metrics aligns with broader industry shifts toward cost-efficient, data-driven healthcare solutions. With cardiovascular care being a significant cost driver, Daxor's technology aims to address a critical gap in fluid status measurement, potentially transforming clinical and financial performance in high-cost medical conditions.

Market Adoption
How quickly cardiovascular programs integrate BVA technology into clinical workflows.
Regulatory Compliance
Whether Daxor can sustain FDA clearance advantages amid potential competitive product offerings.
Financial Impact
The pace at which BVA adoption reduces 30-day readmissions and optimizes length of stay.